Aktuellt
SENASTE
Redeye continues to see potential for stellar growth ahead for Genovis following its Q2 2023 report, which showcased 40% sales growth coupled with 20% EBIT margins. In this report we discuss the report, recent developments and slightly upwards adjust our base case.
LÄS MER
